hrp0084p2-408 | GH & IGF | ESPE2015

Does Skeletal Disproportion in Children with Idiopathic Short Stature Influence Response to GH Therapy?

Cutfield Wayne S , Lindberg Anders , Hofman Paul , Derraik Jose , Geffner Mitchell E , Camacho-Hubner Cecilia

Background: Children with ISS have an array of causes that lead to short stature and/or poor growth velocity. Genetic causes of short stature, notably SHOX mutations, can be associated with subtle skeletal disproportion with shorter limbs, manifesting as increased sitting-to-standing height ratios or SDS.Objective and hypothesis: Children with ISS and skeletal disproportions have a diminished growth response to GH treatment compared to chi...

hrp0084p2-449 | Growth | ESPE2015

Risk for Non-Alcoholic Fatty Liver Disease in Young Adults Born Preterm

Breij Laura M , Kerkhof Gerthe F , Hokken-Koelega Anita C S

Background: Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome. Accelerated catch-up in weight during infancy in subjects born term has been associated with increased risk for NAFLD in adulthood, but this association has not been studied in subjects born preterm.Objective and hypotheses: To investigate the associations of birth weight, gain in weight for length and accelerated catch-up in weight in the...

hrp0084p2-497 | Perinatal | ESPE2015

Genetic Variation in the FSH Signalling Pathway Affects Female Reproductive Hormones During Infancy

Henriksen Louise S , Hagen Casper P , Assens Maria , Almstrup Kristian , Main Katharina M

Background: Studies have shown that genetic variations in the FSH pathway (SNPs: FSHB −211G>T, FSHR −29G>A, and FSHR 2039A>G) affect peripubertal levels of serum FSH and age at pubertal onset in girls.Objective and hypotheses: Genetic variations in the FSH pathway reflect circulating levels of female reproductive hormones during the postnatal gonadotropin surge.Method: Blood samples were taken in girls of th...

hrp0084p3-707 | Diabetes | ESPE2015

A Novel Genetic Mutation in a Turkish Family with GCK-MODY

Ucakturk S Ahmet , Gunindi Figen , Demirel Fatma , Elmaogullari Selin , Mengen Eda , Yuksel Bilgin

Background: Maturity-onset diabetes of the young type 2 (MODY2) is an autosomal dominant inherited disease caused by heterozygous inactivating mutations in the glucokinase (GCK) gene. It mostly presents with mild fasting hyperglycaemia. MODY2 accounts for 2%–5% of all diabetes cases. It is treated with diet only, and complications are extremely rare. We presented here a family with MODY2 caused by a novel heterozygous p.E51*(c.151.G>T) mutation of the GCK gene.<p ...

hrp0094p2-101 | Diabetes and insulin | ESPE2021

Disturbances of glucose homeostasis in polytransfused beta-thalassemia patients

Mustapha Noumi , N Khelafi , Y Ferhani , S Sokhal , R Terrak , R Boukari ,

Introduction: β-thalassemia is a hereditary chronic hemolytic anemia characterized by a defect in the synthesis of beta-globin chains, particularly common in the Mediterranean region, southern Asia, and the Middle East (1) Transfusion programs and chelating therapy have greatly extended the life expectancy of patients (2). This has led to an increase in the prevalence of endocrine complications, linked to iron overload (3) including abnormalities in gluco...

hrp0094p2-230 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

The utility of continuous glucose monitoring systems in the management of children with persistent hypoglycaemia

Vijayanand Sathyakala , Stevenson Paul G , Grant Maree , Choong Catherine S , Davis Elizabeth A , Abraham Mary B ,

Background: Glucose monitoring is vital in children with persistent hypoglycaemia to reduce the risk of adverse neuro-behavioural outcomes1. Continuous glucose monitoring (CGM) systems provide real-time glucose levels however; information on its usefulness in monitoring glucose levels in this cohort is limited2, 3.Objective: To ascertain the effectiveness of CGM and to evaluate parents’ experie...

hrp0094p2-369 | Pituitary, neuroendocrinology and puberty | ESPE2021

6-Month GnRHa Formulations Are a Good Choice During the COVID-19 Pandemic and Beyond

R. Benson Matthew , N. Atkinson Stuart , M. Boldt-Houle Deborah , Miller Bradley S. ,

Introduction: Achieving/maintaining effective hormone suppression is fundamental in treating Central Precocious Puberty(CPP). CPP patients are vulnerable to late dosing as they cannot self-administer and require clinic/hospital visits for injections, currently exacerbated by COVID-19. In children, the hypothalamic-pituitary-gonadal axis may rebound faster than elderly oncology patients, so hormone escapes are possible with late dosing. Additionally, the stimul...

hrp0097t16 | Section | ESPE2023

Dose dependent risks of glucocorticoid treatment in classic CAH

Saragolou Kyriakie , Casteràs Anna , Will Charlton R , Barnes Chris , Thornton Paul

Introduction: In congenital adrenal hyperplasia (CAH), glucocorticoid (GC) treatment must perform two functions – to replace cortisol deficiency and to suppress the excess production of adrenal androgens. Unfortunately, androgen suppression usually requires supraphysiologic GC doses, which are associated with serious comorbidities. Our study examined the exposure or dose-dependent relationships between GCs and GC-related adverse events (GCRAEs) and comor...

hrp0097p1-425 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Recombinant human growth hormone treatment for osteogenesis imperfecta: report of two cases

Eduardo Cruvinel Pinto Luís , Scheidemantel Aline , Junqueira Soares Gabriel , Ângela Ramires de Carvalho Julienne

Background: Osteogenesis imperfecta (OI) is a genetic connective tissue disorder with variable phenotype, mainly characterized by bone fragility, short stature and non-skeleton findings. Since growth failure is a predominant feature of OI, recombinant human growth hormone (rhGH) has been suggested as a potential intervention. We describe two boys with OI type I treated with rhGH.Case Reports: Patient 1 had the first frac...

hrp0097p1-42 | Diabetes and Insulin | ESPE2023

Type 1 diabetes in the covid pandemic: what changed?

Diogo Rui , Rua Inês , Cardoso Rita , Dinis Isabel , Mirante Alice , Serra-Caetano Joana

Introduction: The COVID-19 pandemic adversely impacted general access to healthcare. An association between SARS-CoV-2 infection and new-onset type 1 Diabetes (T1D), a more severe disease at diagnosis and a worsening diabetes control have been described.Aim: To evaluate COVID-19 pandemic’s impact in incidence and presentation of T1D on paediatric patients.Material and Methods:</strong...